Drugs / PF-08049820
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07597928 | May → Aug 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07284173 | Nov → Dec 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07190430 | Oct → Dec 2025 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07172321 | Sep → Oct 2025 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06686797 | Nov 2024 → Feb 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07216027 | Nov 2025 → Feb 2028 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08049820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07597928 ↗ |
| Route | Oral | “take a single dose of the study medicine or placebo as liquid by mouth” NCT06686797 ↗ |